1. Search Result
Search Result
Results for "

platelet aggregation induced by ADP

" in MedChemExpress (MCE) Product Catalog:

74

Inhibitors & Agonists

2

Peptides

16

Natural
Products

7

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134216
    MAHMA NONOate
    1 Publications Verification

    Endogenous Metabolite NO Synthase Cardiovascular Disease
    MAHMA NONOate is a NO donor. MAHMA NONOate effectively inhibits platelet aggregation induced by either collagen or ADP .
    MAHMA NONOate
  • HY-N1717

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak platelet aggregation inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation .
    2-Acetylbenzoic acid
  • HY-15284

    PCR 4099

    P2Y Receptor Cardiovascular Disease
    Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel
  • HY-15284A

    PCR 4099 hydrochloride

    P2Y Receptor Cardiovascular Disease
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel hydrochloride
  • HY-175986

    Prostaglandin Receptor Inflammation/Immunology
    IP receptor agonist 1 (compound 6c-14S) is an orally active IP receptor agonist, with an IC50 of 0.15 μM for inhibiting platelet aggregation induced by ADP (HY-W010918,300 μM) in rabbit platelet-rich plasma. IP receptor agonist 1 can be used for study of Pulmonary arterial hypertension .
    IP receptor agonist 1
  • HY-P1702

    Integrin Others
    GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC50= 0.9 μM) .
    GR83895
  • HY-N14932

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    Aggreceride A is a platelet aggregation inhibitor. Aggreceride A shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
    Aggreceride A
  • HY-134353A

    Adenosine 5'-(β-thiodiphosphate) trisodium

    PGE synthase Cardiovascular Disease
    ADP-β-S (trisodium) is an ADP analog and partial agonist. ADP-β-S (trisodium) induces human platelet aggregation and inhibits PGE1-stimulated adenylate cyclase .
    ADP-β-S trisodium
  • HY-N14933

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    Aggreceride B is a platelet aggregation inhibitor. Aggreceride B shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
    Aggreceride B
  • HY-N14934

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    Aggreceride C is a platelet aggregation inhibitor. Aggreceride C shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
    Aggreceride C
  • HY-116850

    EG626; Phthalazinol; SC-32840

    Phosphodiesterase (PDE) Neurological Disease
    Oxagrelate is a specific inhibitor of cyclic adenosine monophosphate phosphodiesterase and exhibits concentration-dependent inhibition of collagen- and ADP-induced platelet aggregation in vitro .
    Oxagrelate
  • HY-123669

    P2Y Receptor Cardiovascular Disease
    R-138727, the thiol-containing active metabolite of Prasugrel, is an irreversible platelet P2Y12 receptor inhibitor. R-138727 inhibits ADP-induced platelet aggregation .
    R-138727
  • HY-15284B

    PCR 4099 (Maleic acid)

    P2Y Receptor Cardiovascular Disease
    Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel (Maleic acid)
  • HY-176060

    Histamine Receptor Adrenergic Receptor 5-HT Receptor Cardiovascular Disease Cancer
    Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis .
    Platelet aggregation-IN-3
  • HY-N13135

    Others Cardiovascular Disease
    Kadsutherin G (compound 3) is a lignin isolated from Kadsura. Kadsutherin G inhibits adenosine diphosphate (ADP)-induced platelet aggregation by 33.1 % .
    Kadsutherin G
  • HY-W419570

    P2Y Receptor Cardiovascular Disease
    (Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC50 of 15 μM) .
    (Rac)-BX 048
  • HY-113113

    13,14-Dihydroprostaglandin E1

    Endogenous Metabolite Metabolic Disease
    13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
    13,14-Dihydro PGE1
  • HY-105514

    Others Cardiovascular Disease
    KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research .
    KP-10614
  • HY-173207

    Thrombin Cardiovascular Disease
    Antiplatelet agent 3 (Compound K-10) is a compound with anti-platelet aggregation activity. The IC50 values for platelet aggregation induced by ADP, AA and COL are 2.55, 3.22 and 2.09 mg/mL, respectively. Antiplatelet agent 3 is expected to be used in the research of cardiovascular diseases .
    Antiplatelet agent 3
  • HY-N7614

    Schidigerasaponin F2; Timosaponin AII

    Others Cardiovascular Disease
    Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation .
    Anemarrhenasaponin A2
  • HY-167848

    XL-118

    Others Cardiovascular Disease
    DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
    DMP-728 free base
  • HY-167686

    Homopisatin

    Integrin Cardiovascular Disease
    Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .
    Variabilin
  • HY-18740A

    HL 725

    Phosphodiesterase (PDE) Metabolic Disease
    Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of platelet CAMP phosphodiesterase (PDE), with an IC50 of 0.25 nM. Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine .
    Trequinsin hydrochloride
  • HY-15284S1

    PCR 4099-d3

    P2Y Receptor Cardiovascular Disease
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel-d3
  • HY-15284S

    PCR 4099-d5

    Isotope-Labeled Compounds P2Y Receptor Cardiovascular Disease
    Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel-d5
  • HY-122048

    AR-C67085MX; PSB 0413; FPL 67085

    P2Y Receptor Cardiovascular Disease
    AR-C67085 (PSB 0413; FPL 67085) is a potent platelet P2T receptor antagonist with an pIC50 value of 8.60. AR-C67085 inhibits ADP-induced platelet aggregation .
    AR-C67085
  • HY-15284S2

    PCR 4099-d4

    P2Y Receptor Cardiovascular Disease
    Prasugrel-d4 is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel-d4
  • HY-N13134

    Others Cardiovascular Disease
    Kadsutherin F (compound 2) is a lignin that can be isolated from Kadsura. Kadsutherin F has an inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation with an inhibition rate of 49.47% .
    Kadsutherin F
  • HY-113723

    P2Y Receptor Cardiovascular Disease
    MRS2298? is a potent acyclic P2Y1 receptor antagonist with a Ki of 29.6 nM. MRS2298 inhibits the ADP-induced aggregation of human platelets with an IC50 of 62.8 nM. MRS2298 inhibits Ca 2+ rise in platelets with an IC50 of 810 nM .
    MRS2298
  • HY-131776A

    2-Chloroadenosine 5′-diphosphate sodium

    Adenylate Cyclase HSP Cardiovascular Disease
    2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sodium is a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase . 2-Chloro-ADP sodium inhibits mortalin nucleotide-binding domain (NBD) with a Ki of 45.05 μM .
    2-Chloro-ADP sodium
  • HY-15284R

    PCR 4099 (Standard)

    Reference Standards P2Y Receptor Cardiovascular Disease
    Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel (Standard)
  • HY-112658

    Adrenergic Receptor Adenosine Receptor Endocrinology
    p-Iodoclonidine hydrochloride is a partial agonist of α2-adrenergic receptor. p-Iodoclonidine hydrochloride also has minimal agonist activity in inhibiting adenylate cyclase in platelet membranes, and potentiates ADP induced platelet aggregation with an EC50 of 1.5 μM .
    p-Iodoclonidine hydrochloride
  • HY-15284AR

    PCR 4099 hydrochloride (Standard)

    Reference Standards P2Y Receptor Cardiovascular Disease
    Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel hydrochloride (Standard)
  • HY-116613

    Prostaglandin Receptor Cardiovascular Disease Endocrinology
    FR-181877 (compound 4) is a non-prostaglandin PGI2 agonist. FR-181877 inhibits ADP (HY-W010918)-induced human platelet aggregation with an IC50 value of 0.081 μM .
    FR-181877
  • HY-108633

    PARP Cancer
    AR-C66096 (FPL 66096) tetrasodium is a selective platelet P2YT receptor antagonist. AR-C66096 tetrasodium effectively blocks ADP-induced platelet aggregation. AR-C66096 tetrasodium can be used in the research of thromboembolism .
    BYK 49187
  • HY-15284S3

    PCR 4099-13C6

    Isotope-Labeled Compounds P2Y Receptor Cardiovascular Disease
    Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel-13C6
  • HY-101370

    P2X Receptor Metabolic Disease
    2-Methylthio-ATP tetrasodium is a non-specific P2-receptor agonist. 2-Methylthio-ATP tetrasodium causes noncompetitive inhibition of ADP-induced human platelet aggregation .
    2-Methylthio-ATP tetrasodium
  • HY-165434

    EL 784

    Prostaglandin Receptor Cardiovascular Disease
    Naxaprostene is a prostacyclin analogue. Naxaprostene was much more selective for IP receptors and tended towards partial agonism. Naxaprostene inhibits ADP-induced platelet aggregation. It has been shown to prevent rabbit carotid artery thrombosis.
    Naxaprostene
  • HY-131776

    2-Chloroadenosine 5′-diphosphate

    Adenylate Cyclase HSP Cardiovascular Disease
    2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sis a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase . 2-Chloro-ADP inhibits mortalin nucleotide-binding domain (NBD) with a Ki of 45.05 μM .
    2-Chloro-ADP
  • HY-124371

    Phosphodiesterase (PDE) Cardiovascular Disease
    Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .
    Amentoflavone hexaacetate
  • HY-19638A
    Cangrelor tetrasodium
    4 Publications Verification

    AR-C69931MX tetrasodium

    P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
    Cangrelor tetrasodium
  • HY-N4266

    Others Cardiovascular Disease
    Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (IC50=25.18 μM) .
    Vinaginsenoside R8
  • HY-136142

    Drug Metabolite Others
    Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel chloride impurity
  • HY-123669A

    P2Y Receptor Cardiovascular Disease
    Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .
    trans-R-138727
  • HY-19638

    AR-C69931MX

    P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .
    Cangrelor
  • HY-137591

    Drug Metabolite Endocrinology
    13,14-Dihydro-15-keto-PGE1 is an inactive metabolite of PGE1. 13, 14-Dihydro-15-Keto-pGE1 inhibited platelet aggregation in ADP-induced human isolated platelet-rich plasma with IC50 14.8 μg/mL .
    13,14-Dihydro-15-keto-PGE1
  • HY-113096

    PGD1

    Endogenous Metabolite Metabolic Disease
    Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC50 value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .
    Prostaglandin D1
  • HY-W686186

    Drug Metabolite P2Y Receptor Cardiovascular Disease
    Prasugrel hydroxy thiolactone (compound M18) is a metabolite of Prasugrel (HY-15284). Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation .
    Prasugrel hydroxy thiolactone
  • HY-119860

    ONO 41483

    Drug Derivative Cardiovascular Disease
    Ataprost (ONO 41483) is an orally active Carboprostacyclin (HY-112322) analogue. Ataprost exhibits 2.6 times more active than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Ataprost has the ability to relieve coronary spasm .
    Ataprost
  • HY-U00235

    Integrin Inflammation/Immunology
    SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
    SR121566A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: